查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863478

器官移植診斷市場按檢測類型、器官類型、技術、應用和最終用戶分類－2025-2032年全球預測

Organ Transplant Diagnostics Market by Test Type, Organ Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，器官移植診斷市場將成長至 80.8 億美元，複合年成長率為 7.69%。

關鍵市場統計數據
基準年 2024 44.6億美元
預計年份：2025年 48億美元
預測年份 2032 80.8億美元
複合年成長率 (%) 7.69%

器官移植診斷的策略概述：重點關注當前臨床重點和影響其應用的營運趨勢

器官移植診斷處於精準醫療、實驗室創新和複雜臨床流程的交會點，快速且準確的檢測決定著移植結果和病患的生存率。診斷方法涵蓋基因譜分析、組織相容性評估、分子監測和血清學檢測，每種方法都具有獨特的臨床價值，從捐贈者選擇到長期移植後監測均發揮作用。近年來，臨床環境對高解析度分子數據和操作簡便性的需求日益成長，以滿足緊迫的臨床時間要求，這迫使供應商和實驗室重新評估平台互通性和結果報告策略。

因此，臨床和商業性相關人員必須了解檢測途徑如何與移植計畫的物流、免疫抑制策略和感染監測通訊協定整合。結合臨床背景解讀檢測結果，有助於降低免疫風險、指南免疫調節並改善器官分配決策。隨著該領域的不斷發展，決策者需要在新型高解析度檢測和分析技術與實驗室認證、報銷機制和供應連續性等實際限制因素之間取得平衡。鑑於這些優先事項，本執行摘要總結了影響診斷技術應用的關鍵轉折點，指出了基於細分市場的機遇，並為希望將證據轉化為營運優勢的領導者提出了切實可行的建議。

技術創新、監管重點和臨床工作流程重組正在推動移植診斷關鍵性再形成。

移植診斷領域正經歷變革性的轉變，這主要得益於技術進步、監管調整以及臨床實踐模式的演變。次世代定序技術和高靈敏度分子檢測顯著提高了診斷準確性，實現了更精準的供受者匹配，並能更早發現排斥反應和感染疾病。同時，檢測自動化和數位化報告技術的進步減少了人工操作，並加快了臨床決策週期，迫使移植團隊重新設計工作流程，以確保及時獲得檢測結果。

同時，支付方和醫療系統越來越重視基於價值的醫療結果，要求診斷試劑供應商透過真實世界數據和成本效益分析來證明其臨床效用。監管機構也日益關注檢測標準化和互通性，鼓勵供應商採用統一的通訊協定並參與外部品質評估。此外，供應鏈韌性已成為一項策略重點，相關人員強調試劑來源多元化和檢驗的緊急時應對計畫。這些變化共同創造了一種市場環境，除了技術差異化之外，還需要證據支持、供應穩定和營運整合，才能在移植中心和診斷實驗室中獲得廣泛應用。

預測美國關稅政策變化對診斷供應鏈、籌資策略和臨床准入的累積影響

改變關稅結構的政策措施會對診斷平台和耗材的可用性、成本基礎和籌資策略產生重大影響，尤其會對依賴專業檢測和國際供應鏈的移植項目造成顯著衝擊。關稅上漲時，實驗室和醫院通常會尋找替代供應商、透過集中採購整合採購，並加快相容試劑和設備的現場檢驗。同時，關稅政策的降低或澄清通常能夠恢復可預測的採購前置作業時間，並支持因成本不確定性而推遲的平台升級投資。

事實上，對移植診斷產業的累積影響包括庫存管理實踐的變更、重新評估供應商合約以納入關稅相關條款，以及重新重視區域製造夥伴關係以保護關鍵供應鏈。重點，診斷決策者也必須考慮間接影響。關稅帶來的成本壓力可能會延遲新檢測方法的檢驗，壓縮專業實驗室的利潤率，並影響其繼續在國內採購還是從國外採購的決策。為了減輕營運中斷的影響，臨床實驗室和醫院系統應提高供應鏈的透明度，重新談判包含服務水準保護條款的條款，並優先考慮建立多元化的供應商生態系統，以降低單一供應商遭受關稅衝擊的風險。

詳細的分割分析將診斷方式、器官特異性工作流程、平台技術、臨床應用和最終用戶能力連結起來

細緻的細分方法揭示了不同檢測類型、器官特異性適應症、平台技術、應用領域和終端用戶環境之間存在的顯著需求促進因素和營運重點。檢測類型區分了基因檢測（包括DNA定序和SNP基因型鑒定）與組織相容性檢測流程（例如交叉配對試驗和HLA型檢測），並進一步區分了分子方法（例如次世代定序和PCR）與血清學技術（包括ELISA和流式細胞技術）。這些診斷方法直接滿足器官特異性需求，心臟、腎臟、肝臟、肺臟和胰臟移植項目對敏感度、通量和周轉時間等特性各有重點。腎臟和肝臟移植計畫也因腦死捐贈者與活體捐贈者流程的不同而存在差異，這會影響移植前配對和移植後後續觀察的需求。

從技術角度來看，ELISA 和流式細胞技術仍然是許多實驗室的基礎技術，而微陣列平台、標靶或全基因組定序以及先進的 PCR 技術則支援更深入的免疫遺傳學分析。從應用角度來看，移植前配型活動（例如交叉檢測和 HLA 匹配）需要快速、高度特異性的結果來確定器官分配。同時，移植後監測著重於感染篩檢和排斥反應監測，需要連續採樣和可靠的定量分析。最終用戶環境涵蓋診斷中心、醫院和研究實驗室，並進一步細分為院內實驗室和獨立實驗室、綜合醫院和專科移植中心以及研究機構，這些機構正在推動實驗性檢測的早期應用。這些細分結構共同突顯了在自動化、數據整合和臨床檢驗方面進行投資能夠產生最大營運和臨床影響的領域。

區域趨勢和戰略意義：影響美洲、歐洲、中東和非洲以及亞太地區診斷技術應用和普及的因素

區域趨勢對診斷技術的可近性、監管預期和商業策略產生了深遠影響，美洲、歐洲、中東和非洲地區以及亞太地區呈現出截然不同的模式。在美洲，大型學術移植中心和綜合檢測網路往往推動高解析度分子偵測的早期應用，而採購方式也越來越重視能夠減輕營運負擔的整合供應商服務解決方案。向東北方向的歐洲、中東和非洲地區發展，由於法規結構和報銷體系的多樣性，供應商需要投資於區域性證據產生和靈活的定價策略。此外，互通性和外部品質保證也日益受到重視。

在亞太地區，醫院基礎設施的快速投資和移植項目的擴張為集中式和分散式檢查模式都創造了巨大的成長潛力。然而，區域供應鏈的差異和各地監管政策的不同要求企業採取適應性強的市場進入策略。總而言之，這些區域趨勢凸顯了在地化市場准入、區域性檢驗數據以及與領先的移植中心建立合作夥伴關係的重要性，以加速臨床應用並確保服務的永續提供。

競爭格局和企業級策略結合平台創新、臨床夥伴關係和服務模式，以推動市場採納。

移植診斷生態系統中的主要企業透過平台廣度、檢測能力、監管專業知識以及降低臨床實驗室採用門檻的服務模式來脫穎而出。成熟的平台供應商強調整合檢測、自動化和資料管理的解決方案，使醫院和參考實驗室能夠簡化檢驗和報告流程。同時，專業的分子診斷技術開發人員專注於高解析度HLA型檢測、標靶定序panel和超靈敏排斥標記等細分領域檢測，並經常與臨床實驗室合作進行共同開發和真實世界資料收集。

除了產品創新，成功的公司還會投資於供應鏈韌性、本地技術支援，並建立清晰的臨床效用故事，以引起移植項目和支付方的共鳴。供應商與移植中心之間的策略聯盟透過早期准入計劃和合作研究加速產品應用，而合約實驗室網路和診斷服務供應商透過提供可擴展的檢測能力來擴大覆蓋範圍。最後，優先考慮互通資料解決方案和可操作報告格式的公司能夠提高臨床團隊的接受度，因為這些功能可以直接支援更快的臨床決策和更好的患者預後。

為產業領導者提供切實可行的建議，以協調創新、供應鏈韌性和臨床參與，從而加速技術推廣應用。

我們鼓勵產業領導者優先考慮務實的、分階段的方法，在臨床創新和營運可靠性之間取得平衡，以確保移植項目能夠持續採用這些技術。首先，將研發投資與具有高影響力的臨床應用案例結合，優先開發已被證實能夠改善分配決策、排斥反應檢測和感染監測的檢測方法，同時規劃嚴格的真實世界檢驗。其次，透過多源策略和區域製造夥伴關係關係來強化供應鏈，最大限度地降低外部政策突變帶來的風險，並確保關鍵工作流程所需試劑的持續供應。

同時，需要投資於無縫數據整合和報告標準，以減輕移植臨床醫生的認知負擔，並實現多中心比較。銷售團隊應促進與主要移植中心合作產生證據，並設計靈活的商業模式，以適應醫院的採購週期和實驗室認證要求。最後，可以提供結合培訓、技術支援和結果追蹤的模組化服務，以促進快速實施和持續改進，從而將臨床證據轉化為長期專案應用。

該研究基於透明的調查方法，明確指出了資料來源、檢驗方法、分析框架以及支持其研究結果的局限性。

本研究整合了對同儕審查的臨床文獻、監管指南文件、技術白皮書和檢驗的實驗室實踐資源進行系統性回顧的結果，並輔以來自移植中心、診斷實驗室和採購部門專家的定性意見。分析架構包括移植診斷工作流程的橫斷面流程圖繪製、技術能力比較以及專注於供應鏈和政策差異的情境分析。研究結果透過跨多個資料來源的三角驗證進行檢驗，以確保其一致性並識別臨床意圖與實驗室實踐之間的差距。

限制包括專有檢測方法的已發布性能指標存在差異，以及各實驗室報告規範的不一致。我們的調查方法旨在透過強調可重複的標準和透明的假設來減輕這些限制。在缺乏原始數據的情況下，我們諮詢了專家，以闡明操作影響和實施障礙。這種方法提供了一種兼顧嚴謹性和實用性的綜合方法，對參與診斷選擇、實驗室實施和臨床專案設計的相關人員具有重要意義。

對優先趨勢、策略要務和協作行動進行關鍵性綜合分析，將診斷創新轉化為臨床成果

摘要，器官移植診斷領域正處於轉折點，高解析度檢測和改進的操作模式為改善臨床療效提供了清晰的路徑——前提是相關人員能夠解決與證據生成、供應永續性和工作流程整合相關的實際限制。雖然技術進步能夠實現更精準的供受者配對和更早發現不利事件，但其應用取決於供應商、實驗室和移植中心能否證明其臨床效用、確保穩定的供應，並將檢測結果整合到可操作的診療路徑中。此外，區域和政策趨勢要求針對檢驗、定價和分銷採取符合當地監管和報銷環境的客製化方法。

決策者在評估各種機會時，應重視多方合作的重要性——將臨床科學家、實驗室主任、採購負責人和行業合作夥伴聚集在一起，推動診斷解決方案的試點、檢驗和規模化，從而改善患者照護——使相關人員能夠將技術潛力轉化為可衡量的臨床影響和永續的營運模式，以支持現在和未來的移植項目。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將供體來源的遊離DNA檢測納入腎移植受者早期排斥反應檢測的準確性
  • 引入多重免疫檢測檢測方法，用於預測肝臟移植受者的急性排斥反應並制定個人化的免疫抑制治療方案
  • 開發人工智慧驅動的影像分析演算法，以識別移植血管疾病的早期徵兆並量化移植血管灌注。
  • 快速照護現場基因表現譜分析技術在心臟移植病患免疫狀態監測的應用
  • 利用常溫機械灌註生物標記擴大肺移植中供體器官活力的評估

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 器官移植診斷市場（依檢測類型分類）

  • 基因檢測
    • DNA定序
    • SNP基因基因型鑒定
  • 組織相容性
    • 交叉配對試驗
    • HLA型檢測
  • 分子
    • 次世代定序
    • PCR
  • 血清學
    • ELISA
    • 流式細胞技術

9. 按器官類型分類的器官移植診斷市場

  • 心
  • 腎
    • 已故捐贈者
    • 活體捐贈者
  • 肝
    • 已故捐贈者
    • 活體捐贈者
  • 肺
  • 胰臟

第10章 依技術分類的器官移植診斷市場

  • ELISA
    • 競爭性ELISA
    • 夾心ELISA
  • 流式細胞技術
    • 細胞分選
    • 免疫表現型分析
  • 微陣列
    • 表達式數組
    • SNP晶片
  • 次世代定序
    • 標靶定序
    • 全基因測序
  • PCR
    • 數位PCR
    • 即時PCR

第11章 依應用分類的器官移植診斷市場

  • 移植後監測
    • 傳染病篩檢
    • 拒收監測
  • 移植前相容性測試
    • 橫斷面研究
    • HLA配對

第12章 依最終使用者分類的器官移植診斷市場

  • 診斷中心
    • 醫院檢查室
    • 獨立檢驗機構
  • 醫院
    • 綜合醫院
    • 移植中心
  • 研究所

第13章 各地區器官移植診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 器官移植診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國器官移植診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Holding AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • bioMerieux SA
    • QIAGEN NV
    • PerkinElmer, Inc.
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
Product Code: MRR-5C6F41F5B031

The Organ Transplant Diagnostics Market is projected to grow by USD 8.08 billion at a CAGR of 7.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.46 billion
Estimated Year [2025] USD 4.80 billion
Forecast Year [2032] USD 8.08 billion
CAGR (%) 7.69%

Strategic overview of organ transplant diagnostics highlighting current clinical priorities and operational dynamics shaping adoption

Organ transplant diagnostics sit at the intersection of precision medicine, laboratory innovation, and complex clinical workflows, where timely and accurate testing determines graft outcomes and patient survival. Diagnostic modalities span genetic profiling, histocompatibility assessment, molecular surveillance, and serological interrogation, each contributing distinct clinical value from donor selection through long-term posttransplant monitoring. Recent years have seen the clinical community demand both higher resolution molecular data and operational simplicity to fit within tight clinical timelines, driving vendors and laboratories to re-evaluate platform interoperability and result turnaround strategies.

Consequently, clinical and commercial stakeholders must appreciate how testing pathways integrate with transplant program logistics, immunosuppression strategies, and infection surveillance protocols. When interpreted alongside clinical context, test outputs reduce immunologic risk, guide immunomodulation, and improve allocation decisions. As the sector evolves, decision-makers will need to balance novel high-resolution assays and analytics with practical constraints such as laboratory accreditation, reimbursement frameworks, and supply continuity. With these priorities in mind, this executive summary synthesizes the primary inflection points shaping diagnostics adoption, identifies segmentation-driven opportunities, and outlines pragmatic recommendations for leaders aiming to translate evidence into operational advantage.

Critical transformative shifts reshaping transplant diagnostics driven by technological innovation, regulatory focus, and clinical workflow realignment

The landscape of transplant diagnostics is undergoing transformative shifts driven by converging technological advances, regulatory recalibration, and evolving clinical practice patterns. Next-generation sequencing and high-sensitivity molecular assays have raised the bar for diagnostic resolution, enabling more precise donor-recipient matching and earlier detection of rejection or infection. At the same time, improvements in assay automation and digital reporting have reduced manual steps and enabled faster clinical decision cycles, prompting transplant teams to redesign workflows around timely laboratory inputs.

Simultaneously, payers and health systems are emphasizing value-based outcomes, pushing diagnostics suppliers to demonstrate clinical utility through real-world evidence and cost-offset analyses. Regulatory agencies have become more focused on assay standardization and interoperability, which encourages vendors to pursue harmonized protocols and external quality assessment participation. Moreover, supply chain resilience has emerged as a strategic priority, with stakeholders favoring diversified reagent sources and validated contingency plans. Together, these shifts create a market environment where technological differentiation must be matched by evidence generation, supply stability, and operational integration to win adoption across transplant centers and diagnostic laboratories.

Projected cumulative implications of changes in United States tariff policy on diagnostic supply chains, procurement strategies, and clinical access

Policy actions that alter tariff structures can materially affect the availability, cost base, and procurement strategies for diagnostic platforms and consumables, with significant implications for transplant programs that rely on specialized assays and international supply chains. When tariffs increase, laboratories and hospitals often respond by sourcing alternative suppliers, aggregating purchases through centralized procurement, or accelerating local validation of compatible reagents and instruments. Conversely, reductions or clarifications in tariff policy typically restore predictable procurement lead times and support investment in platform upgrades that were previously deferred due to cost uncertainty.

In practice, the cumulative impact on transplant diagnostics includes shifts in inventory management practices, a reassessment of supplier contracts to include tariff-related clauses, and renewed emphasis on regional manufacturing partnerships to insulate critical supply lines. Importantly, diagnostic decision-makers must also consider indirect effects: tariff-induced cost pressures can slow validation of new assays, compress margins for specialized testing providers, and influence decisions about onshoring versus continued international sourcing. To mitigate operational disruption, clinical laboratories and hospital systems should strengthen supply chain visibility, renegotiate terms to include service-level protections, and prioritize diverse vendor ecosystems that reduce exposure to single-source tariff shocks.

Granular segmentation insights connecting diagnostic modalities, organ-specific workflows, enabling technologies, clinical applications, and end-user capabilities

A nuanced segmentation approach reveals distinct demand drivers and operational imperatives across test types, organ indications, enabling technologies, applications, and end-user settings. Test type distinctions separate genetic assays that include DNA sequencing and SNP genotyping from histocompatibility workflows such as crossmatching and HLA typing, and further differentiate molecular methods like next-generation sequencing and PCR from serological techniques including ELISA and flow cytometry. These diagnostic modalities map directly to organ-specific requirements, where heart, kidney, liver, lung, and pancreas programs prioritize different sensitivity, throughput, and turnaround characteristics; kidney and liver programs further bifurcate based on deceased donor and living donor workflows, affecting pretransplant matching and posttransplant surveillance needs.

From a technology vantage, ELISA and flow cytometry remain foundational for many laboratories, while microarray platforms, targeted or whole genome sequencing, and advanced PCR variants support deeper immunogenetic profiling. Application-wise, pretransplant matching activities such as crossmatch testing and HLA matching demand rapid, high-specificity outputs to inform allocation, whereas posttransplant monitoring focuses on infection screening and rejection surveillance that require longitudinal sampling and reliable quantitation. End-user ecosystems span diagnostic centers, hospitals, and research laboratories, with sub-segmentation into hospital labs versus independent labs, general hospitals versus specialized transplant centers, and research entities that often drive early adoption of experimental assays. Taken together, this segmentation fabric highlights where investments in automation, data integration, and clinical validation will deliver the greatest operational and clinical return.

Region-specific dynamics and strategic implications across Americas, Europe Middle East & Africa, and Asia-Pacific influencing diagnostic deployment and uptake

Regional dynamics exert a profound influence on diagnostic availability, regulatory expectations, and commercial strategies, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, large academic transplant centers and consolidated laboratory networks tend to drive early adoption of high-resolution molecular assays, while procurement approaches increasingly favor integrated vendor-service solutions that reduce operational burden. Transitioning northeast to Europe Middle East & Africa, regulatory frameworks and reimbursement heterogeneity require vendors to invest in localized evidence generation and flexible pricing strategies, and programs often place a premium on interoperability and external quality assurance.

Across Asia-Pacific, rapid investment in hospital infrastructure and expanding transplant programs create high growth potential for both centralized and decentralized testing models, yet regional supply chain considerations and local regulatory variations necessitate adaptive go-to-market approaches. Collectively, these regional patterns underscore the importance of tailored market engagement, region-specific validation data, and collaborative partnerships with leading transplant centers to accelerate clinical acceptance and ensure sustainable service delivery.

Competitive landscape and company-level strategies that combine platform innovation, clinical partnerships, and service models to drive adoption

Leading companies in the transplant diagnostics ecosystem differentiate through a combination of platform breadth, assay performance, regulatory expertise, and service models that reduce implementation friction for clinical laboratories. Established platform vendors emphasize integrated solutions that bundle assays, automation, and data management, enabling hospitals and reference laboratories to streamline validation and reporting. At the same time, specialist molecular innovators focus on niche assays such as high-resolution HLA typing, targeted sequencing panels, and ultra-sensitive rejection markers, often partnering with clinical laboratories for co-development and real-world evidence generation.

Beyond product innovation, successful players invest in supply chain resilience, local technical support, and clear clinical utility narratives that resonate with transplant programs and payers. Strategic partnerships between vendors and transplant centers accelerate adoption through early access programs and collaborative studies, while contract laboratory networks and diagnostic service providers expand reach by offering scalable testing capacity. Finally, companies that prioritize interoperable data solutions and actionable reporting formats create stickiness with clinical teams, as these capabilities directly support faster clinical decisions and better patient outcomes.

Actionable recommendations for industry leaders to synchronize innovation, supply resilience, and clinical engagement to accelerate adoption

Industry leaders should prioritize a pragmatic, phased approach that balances clinical innovation with operational reliability to secure sustained adoption across transplant programs. First, align R&D investments with high-impact clinical use cases, prioritizing assays that demonstrably improve allocation decisions, rejection detection, or infection surveillance while planning rigorous real-world validation. Next, fortify supply chains through multi-sourcing strategies and regional manufacturing partnerships to minimize exposure to external policy shocks and ensure ongoing reagent availability for critical workflows.

Concurrently, invest in seamless data integration and reporting standards that reduce cognitive load for transplant clinicians and support multi-center comparability. Commercial teams should pursue collaborative evidence generation with leading transplant centers and design flexible commercial models that accommodate hospital purchasing cycles and laboratory accreditation requirements. Finally, develop modular service offerings that combine training, technical support, and outcome-tracking to facilitate rapid implementation and continuous improvement, thereby converting clinical proof points into long-term programmatic adoption.

Transparent research methodology describing data sources, validation approaches, analytical frameworks, and limitations informing the insights

This research synthesizes insights from a structured review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and validated laboratory practice resources, supplemented by qualitative inputs from subject matter experts across transplant centers, diagnostic laboratories, and procurement functions. Analytical frameworks included cross-sectional process mapping of transplant diagnostic workflows, technology capability comparisons, and scenario analysis focused on supply chain and policy perturbations. Findings were validated through triangulation across diverse data sources to ensure consistency and to identify points of practical divergence between clinical intent and laboratory operations.

Limitations include variability in publicly available performance metrics for proprietary assays and heterogeneity in reporting practices across centers, which the methodology seeks to mitigate by emphasizing reproducible decision criteria and transparent assumptions. Where primary data gaps remained, expert consultations helped contextualize likely operational impacts and adoption barriers. This approach yields an actionable synthesis that balances rigor with practical relevance for stakeholders involved in diagnostic selection, laboratory implementation, and clinical program design.

Conclusive synthesis of priority trends, strategic imperatives, and collaborative actions to translate diagnostic innovation into clinical outcomes

In sum, the organ transplant diagnostics domain is at an inflection point where higher-resolution assays and improved operational models offer clear paths to better clinical outcomes, provided stakeholders address practical constraints around evidence generation, supply resilience, and workflow integration. Technological advances enable more precise donor-recipient matching and earlier detection of adverse events, but adoption depends on the ability of vendors, laboratories, and transplant centers to demonstrate clinical utility, ensure consistent supply, and embed testing outputs into actionable care pathways. Moreover, regional and policy dynamics require tailored approaches to validation, pricing, and distribution that respect local regulatory and reimbursement landscapes.

As decision-makers evaluate opportunities, the emphasis should remain on multi-stakeholder collaboration: aligning clinical scientists, laboratory leaders, procurement officers, and industry partners to pilot, validate, and scale diagnostic solutions that improve patient care. By doing so, stakeholders can translate technological promise into measurable clinical impact and sustainable operational models that support transplant programs now and into the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of donor-derived cell-free DNA assays to enhance early rejection detection in kidney transplant recipients
  • 5.2. Adoption of multiplex immunoassay panels to predict acute rejection and tailor immunosuppressive regimens for liver transplant patients
  • 5.3. Development of AI-driven imaging algorithms for quantifying graft perfusion and identifying early signs of transplant vasculopathy
  • 5.4. Emergence of rapid point-of-care gene expression profiling to monitor immune status in heart transplant recipients
  • 5.5. Expansion of donor organ viability assessment using normothermic machine perfusion biomarkers in lung transplantation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organ Transplant Diagnostics Market, by Test Type

  • 8.1. Genetic
    • 8.1.1. Dna Sequencing
    • 8.1.2. SnP Genotyping
  • 8.2. Histocompatibility
    • 8.2.1. Crossmatching
    • 8.2.2. Hla Typing
  • 8.3. Molecular
    • 8.3.1. Next Generation Sequencing
    • 8.3.2. Pcr
  • 8.4. Serological
    • 8.4.1. Elisa
    • 8.4.2. Flow Cytometry

9. Organ Transplant Diagnostics Market, by Organ Type

  • 9.1. Heart
  • 9.2. Kidney
    • 9.2.1. Deceased Donor
    • 9.2.2. Living Donor
  • 9.3. Liver
    • 9.3.1. Deceased Donor
    • 9.3.2. Living Donor
  • 9.4. Lung
  • 9.5. Pancreas

10. Organ Transplant Diagnostics Market, by Technology

  • 10.1. Elisa
    • 10.1.1. Competitive Elisa
    • 10.1.2. Sandwich Elisa
  • 10.2. Flow Cytometry
    • 10.2.1. Cell Sorting
    • 10.2.2. Immunophenotyping
  • 10.3. Microarray
    • 10.3.1. Expression Arrays
    • 10.3.2. SnP Arrays
  • 10.4. Next Generation Sequencing
    • 10.4.1. Targeted Sequencing
    • 10.4.2. Whole Genome Sequencing
  • 10.5. Pcr
    • 10.5.1. Digital Pcr
    • 10.5.2. Real Time Pcr

11. Organ Transplant Diagnostics Market, by Application

  • 11.1. Posttransplant Monitoring
    • 11.1.1. Infection Screening
    • 11.1.2. Rejection Monitoring
  • 11.2. Pretransplant Matching
    • 11.2.1. Crossmatch Testing
    • 11.2.2. Hla Matching

12. Organ Transplant Diagnostics Market, by End User

  • 12.1. Diagnostic Centers
    • 12.1.1. Hospital Labs
    • 12.1.2. Independent Labs
  • 12.2. Hospitals
    • 12.2.1. General Hospitals
    • 12.2.2. Transplant Centers
  • 12.3. Research Laboratories

13. Organ Transplant Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Organ Transplant Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Organ Transplant Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Roche Holding AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Siemens Healthineers AG
    • 16.3.5. Danaher Corporation
    • 16.3.6. bioMerieux SA
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. PerkinElmer, Inc.
    • 16.3.9. DiaSorin S.p.A.
    • 16.3.10. Bio-Rad Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ORGAN TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ORGAN TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORGAN TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)